Inequalities in biologics utilization for rheumatoid arthritis according to socioeconomic status.
作者信息
Kwon Oh Chan, Park Min-Chan
机构信息
Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
出版信息
Korean J Intern Med. 2024 Jul;39(4):545-546. doi: 10.3904/kjim.2024.207. Epub 2024 Jul 1.
Abstract
摘要
相似文献
1
Inequalities in biologics utilization for rheumatoid arthritis according to socioeconomic status.
Korean J Intern Med. 2024 Jul;39(4):545-546. doi: 10.3904/kjim.2024.207. Epub 2024 Jul 1.
2
Impact of socioeconomic status on biologics utilization in rheumatoid arthritis: revealing inequalities and healthcare efficiency.
Korean J Intern Med. 2024 Jul;39(4):668-679. doi: 10.3904/kjim.2023.276. Epub 2024 Feb 29.
3
Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.
Cochrane Database Syst Rev. 2016 May 13;2016(5):CD012183. doi: 10.1002/14651858.CD012183.
4
Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
Cochrane Database Syst Rev. 2017 Mar 10;3(3):CD012591. doi: 10.1002/14651858.CD012591.
5
Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
Cochrane Database Syst Rev. 2017 May 8;5(5):CD012657. doi: 10.1002/14651858.CD012657.
6
A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview.
CMAJ. 2009 Nov 24;181(11):787-96. doi: 10.1503/cmaj.091391. Epub 2009 Nov 2.
7
Leucine-rich alpha-2-glycoprotein 1 (LRG1) decrement during biologics therapy and its correlation with disease features and treatment outcomes in rheumatoid arthritis patients.
Clin Rheumatol. 2025 Jul 15. doi: 10.1007/s10067-025-07545-2.
8
The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review.
PLoS One. 2015 Mar 17;10(3):e0119683. doi: 10.1371/journal.pone.0119683. eCollection 2015.
9
Incorporating adjustments for variability in control group response rates in network meta-analysis: a case study of biologics for rheumatoid arthritis.
BMC Med Res Methodol. 2019 Oct 16;19(1):193. doi: 10.1186/s12874-019-0837-2.
10
Predictors of remission in rheumatoid arthritis patients treated with biologics: a systematic review and meta-analysis.
Clin Rheumatol. 2022 Dec;41(12):3615-3627. doi: 10.1007/s10067-022-06307-8. Epub 2022 Aug 16.
本文引用的文献
1
Impact of socioeconomic status on biologics utilization in rheumatoid arthritis: revealing inequalities and healthcare efficiency.
Korean J Intern Med. 2024 Jul;39(4):668-679. doi: 10.3904/kjim.2023.276. Epub 2024 Feb 29.
2
Rheumatoid Arthritis - Common Origins, Divergent Mechanisms.
N Engl J Med. 2023 Feb 9;388(6):529-542. doi: 10.1056/NEJMra2103726.
3
Association of Patient, Prescriber, and Region With the Initiation of First Prescription of Biologic Disease-Modifying Antirheumatic Drug Among Older Patients With Rheumatoid Arthritis and Identical Health Insurance Coverage.
JAMA Netw Open. 2019 Dec 2;2(12):e1917053. doi: 10.1001/jamanetworkopen.2019.17053.
4
Bimodal Function of Anti-TNF Treatment: Shall We Be Concerned about Anti-TNF Treatment in Patients with Rheumatoid Arthritis and Heart Failure?
Int J Mol Sci. 2018 Jun 12;19(6):1739. doi: 10.3390/ijms19061739.
5
The impact of socio-economic status in rheumatoid arthritis.
Rheumatology (Oxford). 2017 Jul 1;56(7):1051-1052. doi: 10.1093/rheumatology/kew428.
6
Understanding emerging treatment paradigms in rheumatoid arthritis.
Arthritis Res Ther. 2011 May 25;13 Suppl 1(Suppl 1):S3. doi: 10.1186/1478-6354-13-S1-S3.
7
Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans.
JAMA. 2011 Feb 2;305(5):480-6. doi: 10.1001/jama.2011.67.
8
Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
Arthritis Rheum. 2006 Aug;54(8):2368-76. doi: 10.1002/art.21978.
Zotero 插件